| Identification | Back Directory | [Name]
5-[(4-[1,1'-Biphenyl]-4-yl-1,6-dihydro-6-oxo-2-pyrimidinyl)thio]-N-hydroxypentanamide | [CAS]
1776116-74-5 | [Synonyms]
MC 1742
MC1742,MC-1742
5-[(4-[1,1'-Biphenyl]-4-yl-1,6-dihydro-6-oxo-2-pyrimidinyl)thio]-N-hydroxypentanamide
Pentanamide, 5-[(4-[1,1'-biphenyl]-4-yl-1,6-dihydro-6-oxo-2-pyrimidinyl)thio]-N-hydroxy- | [Molecular Formula]
C21H21N3O3S | [MDL Number]
MFCD30290158 | [MOL File]
1776116-74-5.mol | [Molecular Weight]
395.47 |
| Chemical Properties | Back Directory | [density ]
1.29±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 100 mM | [form ]
A solid | [pka]
7.51±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
MC 1742 is a novel histone deacetylase inhibitor, which has been shown to induce growth arrest, apoptosis and differentiation in sarcoma cancer stem cells. | [Biological Activity]
MC1742 is a uracil-based hydroxyamide (UBHA) th at acts as a subtype-selective histone deacetylases (HDACs) inhibitor (IC50: class I HDAC1/2/3/8 = 100/110/20/610 nMclass IIB HDAC6/10 = 7/40 nMclass IV HDAC11 = 100 nMclass IIA HDAC4/5/7/9 >50 μM). MC1742 exerts greater antiproliferation potency than SAHA in sarcoma cancer stem cell (CSC) cultures (MC1742/SAHA IC50 in μM = 0.25/1/RD1.12/1.13//MG-631.4/3.92/SK-ES-1 post 72-hr treatment) and effectively reactivates HIV from latency (EC50 = 350 nM; JL at 10.6 cells) by upregulating histone acetylation at the HIV promoter without activating T cells. | [IC 50]
HDAC1: 0.1 μM (IC50); HDAC2: 0.11 μM (IC50); HDAC3: 0.02 μM (IC50); HDAC6: 0.007 μM (IC50); HDAC8: 0.61 μM (IC50); HDAC10: 0.04 μM (IC50); HDAC11: 0.1 μM (IC50) | [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|